{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:28:23Z","timestamp":1792160903389,"version":"4.4.0"},"reference-count":126,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"American Society of Clinical Oncology Young Investigator Award","award":["K08CA270403"],"award-info":[{"award-number":["K08CA270403"]}]},{"name":"Leukemia Lymphoma Society Translation Research Program award","award":["K08CA270403"],"award-info":[{"award-number":["K08CA270403"]}]},{"name":"Jerome Greene Foundation","award":["K08CA270403"],"award-info":[{"award-number":["K08CA270403"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>While antibody-based immunotherapeutic strategies have revolutionized the treatment of B-cell lymphomas, progress in T-cell lymphomas has suffered from suboptimal targets, disease heterogeneity, and limited effective treatment options. Nonetheless, recent advances in our understanding of T-cell biology, the identification of novel targets, and the emergence of new therapies provide hope for the future. In this review, we explore four areas of current and evolving antibody-based strategies for the treatment of peripheral T-cell lymphoma (PTCL): monoclonal antibodies (mAbs), bispecific antibodies (BsAs), chimeric antigen receptor T-cell therapy (CAR-T), and antibody\u2013drug conjugates (ADCs). As part of this discussion, we will also include limitations, lessons learned, and potential future directions.<\/jats:p>","DOI":"10.3390\/cancers16203489","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:45:35Z","timestamp":1729485935000},"page":"3489","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antibody-Based Therapies for Peripheral T-Cell Lymphoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5275-5505","authenticated-orcid":false,"given":"Nazila","family":"Shafagati","sequence":"first","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-3702","authenticated-orcid":false,"given":"Suman","family":"Paul","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rozati","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5911-3873","authenticated-orcid":false,"given":"Cole H.","family":"Sterling","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s11912-022-01310-3","article-title":"Management of Peripheral T-Cell Lymphomas and the Role of Transplant","volume":"24","author":"Foley","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107870","DOI":"10.1016\/j.intimp.2021.107870","article-title":"PD-1 and PD-L1 Inhibitors Foster the Progression of Adult T-Cell Leukemia\/Lymphoma","volume":"98","author":"Soltani","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer Therapy with Antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2165\/11631090-000000000-00000","article-title":"Mogamulizumab: First Global Approval","volume":"72","author":"Subramaniam","year":"2012","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11899-019-00542-8","article-title":"Mechanisms of Resistance to Monoclonal Antibodies (MAbs) in Lymphoid Malignancies","volume":"14","author":"Torka","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid Progression of Adult T-Cell Leukemia\u2013Lymphoma after PD-1 Inhibitor Therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High Remission Rate in T-Cell Prolymphocytic Leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","article-title":"Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-Cell Leukemia\/Lymphoma","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European Phase II Study of Mogamulizumab, an Anti-CCR4 Monoclonal Antibody, in Relapsed\/Refractory Peripheral T-Cell Lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 Expression Predicts Poor Prognosis and Might Be a Potential Therapy Target in Extranodal NK\/T Cell Lymphoma, Nasal Type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab Monotherapy for Patients with Relapsed or Refractory Natural Killer\/T-Cell Lymphoma, Nasal Type: An Open-Label, Single-Arm, Multicenter, Phase 2 Study","volume":"14","author":"Huang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e002123","DOI":"10.1136\/jitc-2020-002123","article-title":"Determinants of Response to Daratumumab in Epstein-Barr Virus-Positive Natural Killer and T-Cell Lymphoma","volume":"9","author":"Mustafa","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 Expression in Peripheral T-Cell Lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a Valuable Tool to Assess CD30 Expression in Peripheral T-Cell Lymphomas: High Correlation with MRNA Levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin\u2019s Lymphoma and Anaplastic Large-Cell Lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A Phase II Study of SGN-30 (Anti-CD30 MAb) in Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma","volume":"146","author":"Leonard","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T Cell Lymphoma: An Open-Label Phase 2 Study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-Cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Modest Activity and Cases of Hyperprogression","volume":"10","author":"Kim","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1016\/S2152-2650(23)01392-7","article-title":"TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis","volume":"23","author":"Iyer","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood.2023020244","article-title":"A Phase 2 Study of Pembrolizumab after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma","volume":"142","author":"Merrill","year":"2023","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00277-016-2818-4","article-title":"Expression of Programmed Cell Death 1 and Programmed Cell Death Ligand 1 in Extranodal NK\/T-Cell Lymphoma, Nasal Type","volume":"96","author":"Jo","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the Treatment of Relapsed or Refractory Extranodal NK\/T-Cell Lymphoma: An Open-Label Phase 2 Study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 Blockade with Pembrolizumab Is Highly Effective in Relapsed or Refractory NK\/T-Cell Lymphoma Failing L-Asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.02367","article-title":"Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer\/T-Cell Lymphoma (GEMSTONE-201): Results from a Single-Arm, Multicenter, Phase II Study","volume":"41","author":"Huang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 Is a Haploinsufficient Suppressor of T Cell Lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e164793","DOI":"10.1172\/jci.insight.164793","article-title":"Hyperprogression of Cutaneous T Cell Lymphoma after Anti-PD-1 Treatment","volume":"8","author":"Gao","year":"2023","journal-title":"JCI Insight"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106614","DOI":"10.1016\/j.leukres.2021.106614","article-title":"CD94 Expression Patterns in Reactive and Neoplastic T-Cell and NK-Cell Proliferations","volume":"108","author":"Fang","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/ITT.S255224","article-title":"TNFR2: Role in Cancer Immunology and Immunotherapy","volume":"10","author":"Yang","year":"2021","journal-title":"Immunotargets Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1158\/1078-0432.CCR-22-2955","article-title":"Targeting the Inducible T-Cell Costimulator (ICOS) in Patients with Relapsed\/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma","volume":"29","author":"Chavez","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3324\/haematol.2022.282220","article-title":"KIR3DL2 May Represent a Novel Therapeutic Target in Aggressive Systemic Peripheral T-Cell Lymphoma","volume":"108","author":"Decroos","year":"2023","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Follicular B-Cell Lymphoma (GALEN): A Multicentre, Single-Arm, Phase 2 Study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3324\/haematol.2014.117531","article-title":"Daratumumab-Mediated Lysis of Primary Multiple Myeloma Cells Is Enhanced in Combination with the Human Anti-KIR Antibody IPH2102 and Lenalidomide","volume":"100","author":"Nijhof","year":"2015","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood-2023-188053","article-title":"Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (Anti-PD-L1) in Refractory\/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial","volume":"142","author":"Querfeld","year":"2023","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Arm, Multicentre, Phase 2 Study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Champiat","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T Cell Malignancies Using CAR-Based Immunotherapy: Challenges and Potential Solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"eabd3595","DOI":"10.1126\/scitranslmed.abd3595","article-title":"TCR \u03b2 Chain-Directed Bispecific Antibodies for the Treatment of T Cell Cancers","volume":"13","author":"Paul","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/cam4.34","article-title":"Identification of Multiple Subclones in Peripheral T-Cell Lymphoma, Not Otherwise Specified with Genomic Aberrations","volume":"1","author":"Yoshida","year":"2012","journal-title":"Cancer Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Faber, M.L., Oldham, R.A.A., Thakur, A., Rademacher, M.J., Kubicka, E., Dlugi, T.A., Gifford, S.A., McKillop, W.M., Schloemer, N.J., and Lum, L.G. (2023). Novel Anti-CD30\/CD3 Bispecific Antibodies Activate Human T Cells and Mediate Potent Anti-Tumor Activity. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1225610"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/toxsci\/kfac052","article-title":"Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys","volume":"189","author":"Harper","year":"2022","journal-title":"Toxicol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"CT024","DOI":"10.1158\/1538-7445.AM2023-CT024","article-title":"Abstract CT024: REDIRECT: A Phase 2 Study of AFM13 in Patients with CD30-Positive Relapsed or Refractory (R\/R) Peripheral T Cell Lymphoma (PTCL)","volume":"83","author":"Kim","year":"2023","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2023-172980","article-title":"Innate Cell Engager (ICE\u00ae) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results","volume":"142","author":"Nieto","year":"2023","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1182\/blood-2023-174250","article-title":"AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)","volume":"142","author":"Moskowitz","year":"2023","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene Maraleucel in Follicular Lymphoma: The Phase 2 TRANSCEND FL Study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-Edited T Cells Expressing a CD7-Specific CAR for the Therapy of T-Cell Malignancies","volume":"130","author":"Srinivasan","year":"2017","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering Naturally Occurring CD7\u2212 T Cells for the Immunotherapy of Hematological Malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"key":"ref_68","first-page":"321","article-title":"Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL\/LBL: First-in-Human Phase 1 Clinical Trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ghobadi, A., Aldoss, I., Maude, S., Bhojwani, D., Wayne, A., Bajel, A., Dholaria, B., Faramand, R., Mattison, R., and Rijneveld, A. (2024). Anti-CD7 Allogeneic WU-CART-007 in Patients with Relapsed\/Refractory T-Cell Acute Lymphoblastic Leukemia\/Lymphoma: A Phase 1\/2 Trial. Res. Sq.","DOI":"10.21203\/rs.3.rs-4676375\/v1"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and Preclinical Efficacy of CD7-Unedited CD7 CAR T Cells for T Cell Malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.21037\/tcr-21-2666","article-title":"Increase of CD3+CD7- T Cells in Bone Marrow Predicts Invasion in Patients with T-Cell Non-Hodgkin\u2019s Lymphoma","volume":"11","author":"Huang","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_73","first-page":"2707","article-title":"CD7 Expression in Reactive and Malignant Human Skin T-Lymphocytes","volume":"23","author":"Alaibac","year":"2003","journal-title":"Anticancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-Cell Malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-136860","article-title":"CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells","volume":"136","author":"Chun","year":"2020","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The Rational Development of CD5-Targeting Biepitopic CARs with Fully Human Heavy-Chain-Only Antigen Recognition Domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed\/Refractory T-Cell Malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor Efficacy and Safety of Unedited Autologous CD5.CAR T Cells in Relapsed\/Refractory Mature T-Cell Lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T Cells Expressing CD5\/CD7 Bispecific Chimeric Antigen Receptors with Fully Human Heavy-Chain-Only Domains Mitigate Tumor Antigen Escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e3515785","DOI":"10.1097\/01.HS9.0000967376.35157.85","article-title":"S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA","volume":"7","author":"Pan","year":"2023","journal-title":"Hemasphere"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2022-166605","article-title":"Clinical Development of Senza5TM CART5: A Novel Dual Population CD5 CRISPR-Cas9 Knocked out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1182\/blood-2022-162222","article-title":"Development of Anti-CD3 Chimeric Antigen Receptor (CAR)-T Cells for Allogeneic Cell Therapy of Peripheral T-Cell Lymphoma (PTCL)","volume":"140","author":"Qian","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel Anti-CD3 Chimeric Antigen Receptor Targeting of Aggressive T Cell Malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of Cutaneous T-Cell Lymphoma with Chimeric Anti-CD4 Monoclonal Antibody","volume":"87","author":"Knox","year":"1996","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical Efficacy of Zanolimumab (HuMax-CD4): Two Phase 2 Studies in Refractory Cutaneous T-Cell Lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II Trial of Zanolimumab (HuMax-CD4) in Relapsed or Refractory Non-Cutaneous Peripheral T Cell Lymphoma","volume":"150","author":"Radford","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical Targeting of Human T-Cell Malignancies Using CD4-Specific Chimeric Antigen Receptor (CAR)-Engineered T Cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-Cell Malignancies Using Anti-CD4 CAR NK-92 Cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/mt.2016.82","article-title":"Superior Therapeutic Index in Lymphoma Therapy: CD30+ CD34+ Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-Cell Attack","volume":"24","author":"Hombach","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00002371-199911000-00001","article-title":"Characterization of a Chimeric T-Cell Receptor with Specificity for the Hodgkin\u2019s Lymphoma-Associated CD30 Antigen","volume":"22","author":"Hombach","year":"1999","journal-title":"J. Immunother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase i Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and Immunological Responses after CD30-Specific Chimeric Antigen Receptor-Redirected Lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhang, S., Gu, C., Huang, L., Wu, H., Shi, J., Zhang, Z., Zhou, Y., Zhou, J., Gao, Y., and Liu, J. (2022). The Third-Generation Anti-CD30 CAR T-Cells Specifically Homing to the Tumor and Mediating Powerful Antitumor Activity. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-14523-0"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T Cells as Consolidation after Autologous Haematopoietic Stem-Cell Transplantation in Patients with High-Risk CD30+ Lymphoma: A Phase 1 Study","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-17-0613","article-title":"Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies","volume":"23","author":"Aftimos","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9\u2013ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED\/REFRACTORY (R\/R) T-CELL MALIGNANCIES","volume":"6","author":"Iyer","year":"2022","journal-title":"Hemasphere"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1182\/blood-2023-184864","article-title":"Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells","volume":"142","author":"Rafei","year":"2023","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/bloodadvances.2022008327","article-title":"Identifying Highly Active Anti-CCR4 CAR T Cells for the Treatment of T-Cell Lymphoma","volume":"7","author":"Watanabe","year":"2023","journal-title":"Blood Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2021-148102","article-title":"CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed\/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma","volume":"138","author":"Grover","year":"2021","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1182\/blood-2022-165971","article-title":"First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed\/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma","volume":"140","author":"Cwynarski","year":"2022","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-Targeting Antibody-Drug Conjugates for the Treatment of T Cell Cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41467-024-45854-3","article-title":"Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies","volume":"15","author":"Ferrari","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2019004118","article-title":"Hepatosplenic T-Cell Lymphoma: A Rare but Challenging Entity","volume":"136","author":"Pro","year":"2020","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Alberti-Violetti, S., Maronese, C.A., Venegoni, L., Merlo, V., and Berti, E. (2021). Primary Cutaneous Gamma-Delta T Cell Lymphomas: A Case Series and Overview of the Literature. Dermatopathology, 8.","DOI":"10.3390\/dermatopathology8040054"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1097\/PAS.0b013e318222dfcd","article-title":"Type II Enteropathy-Associated T-Cell Lymphoma: A Distinct Aggressive Lymphoma with Frequent \u0393\u03b4 t-Cell Receptor Expression","volume":"35","author":"Chan","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41375-021-01385-0","article-title":"Chimeric Antigen Receptor T Cells for Gamma\u2013Delta T Cell Malignancies","volume":"36","author":"Wawrzyniecka","year":"2022","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Zhang, L., Meng, Y., Feng, X., and Han, Z. (2022). CAR-NK Cells for Cancer Immunotherapy: From Bench to Bedside. Biomark. Res., 10.","DOI":"10.1186\/s40364-022-00364-6"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Glienke, W., Esser, R., Priesner, C., Suerth, J.D., Schambach, A., Wels, W.S., Grez, M., Kloess, S., Arseniev, L., and Koehl, U. (2015). Advantages and Applications of CAR-Expressing Natural Killer Cells. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00021"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-Year Results of a Randomized, Phase III Study of Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective Responses in Relapsed T-Cell Lymphomas with Single-Agent Brentuximab Vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and S\u00e9zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrclinonc.2014.159-c1","article-title":"CD30-Targeting Immunoconjugates and Bystander Effects","volume":"12","author":"Masuda","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAS.0000000000000571","article-title":"CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified","volume":"40","author":"Onaindia","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1200\/JCO.2022.40.16_suppl.7559","article-title":"Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Safety and Efficacy Results from the Safety Run-in Period of the Phase 3 ECHELON-3 Study","volume":"40","author":"Bartlett","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"C132","DOI":"10.1158\/1535-7163.TARG-23-C132","article-title":"Abstract C132: SGN-35T: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas","volume":"22","author":"Hamblett","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/protein\/14.12.1035","article-title":"Improved Binding of a Bivalent Single-Chain Immunotoxin Results in Increased Efficacy for in Vivo T-Cell Depletion","volume":"14","author":"Thompson","year":"2001","journal-title":"Protein Eng."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.123711","article-title":"Resimmune, an Anti-CD3\u03b5 Recombinant Immunotoxin, Induces Durable Remissions in Patients with Cutaneous T-Cell Lymphoma","volume":"100","author":"Frankel","year":"2015","journal-title":"Haematologica"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A Phase 1 Trial of SGN-CD70A in Patients with CD70-Positive Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/bloodadvances.2021005714","article-title":"Targeting CD70 in Cutaneous T-Cell Lymphoma Using an Antibody-Drug Conjugate in Patient-Derived Xenograft Models","volume":"6","author":"Wu","year":"2022","journal-title":"Blood Adv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2001879","DOI":"10.1002\/advs.202001879","article-title":"CD38-Targeted Theranostics of Lymphoma with 89Zr\/177Lu-Labeled Daratumumab","volume":"8","author":"Kang","year":"2021","journal-title":"Adv. Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/20\/3489\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:13:31Z","timestamp":1760112811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/20\/3489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":126,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cancers16203489"],"URL":"https:\/\/doi.org\/10.3390\/cancers16203489","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}